Uncovering targets and molecular pathways for personalizing treatment in epilepsy.

Abstract excerpt

INTRODUCTION: Despite licensing many new antiseizure drugs over the last few decades, the proportion of pharmacoresistant epileptic seizures has remained largely unchanged at about 30%. However, recent progress in genetics has revealed new and more specific therapeutic targets that can be addressed through improved drug design and advancements in gene therapy, such as improved antisense oligonucleotide chemistry....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Drug Design
• Share to Alleles
• Share to Anticonvulsants